HopeStage
Back to all studies
SuspendedNCT02724917

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

This study evaluates the safety of APN1125 for people with schizophrenia.

Medication studyAges 18–45United States
The study in practice

Understand this study

What is this study about?

This study evaluates the safety of APN1125 for people with schizophrenia.

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 45 years. Other eligibility criteria apply.

Listed locations
Long BeachSee all locations and recruitment
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateApril 2016
Recruitment status
Suspended
Enrollment listed in the registry
30
Sponsor
CoMentis
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States
Age range
From 18 Years to 45 Years
Official registry ID
NCT02724917
Official title
Show the full official title

A Phase 1b/2a, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Recruitment & locations

Suspended

Long Beach

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the safety of APN1125 for people with schizophrenia.

Who is behind this study?

The study sponsor is CoMentis.

Does this study involve medication?

Yes. The study involves medication, including APN1125 and Placebo.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 45 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as suspended.

Want to explore more studies?

Explore studies